Accession Number:

ADA467918

Title:

Determination of Antibiotic Efficacy Against Bacillus Anthracis in a Mouse Aerosol Challenge Model

Descriptive Note:

Journal article

Corporate Author:

ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FORT DETRICK MD BACTERIOLOGY DIV

Report Date:

2007-04-01

Pagination or Media Count:

9.0

Abstract:

An anthrax-spore aerosol infection mouse model was developed as a first test of in vivo efficacy of antibiotics identified as active against Bacillus anthracis. Whole-body, LD50 aerosol challenge doses in a range of 1.9 x103 to 3.4 x 104 with spores of the fully virulent Ames strain were established for three inbred and one outbred mouse strain AJ, BALBc, C57BL and Swiss Webster. The BALBc strain was further developed as a model for antibiotic efficacy. Time-course microbiological examination of tissue burdens in mice after challenge showed that spores could remain dormant in the lungs while vegetative cells disseminated to the mediastinal lymph nodes and then to the spleen accompanied with bacteremia. For antibiotic efficacy studies, BALBc mice were challenged with 50-100 LD50 of spores followed by intraperitoneal i.p. injection of either ciprofloxacin 30 mgkg q12h, or doxycycline 40 mgkg q6h. A control group was treated with PBS q6h. Treatment was begun 24 h after challenge in groups of 10 mice for 14 or 21 days. The PBS-treated control mice all succumbed 1010 to inhalation anthrax infection within 72 h. Sixty-day survival rates for ciprofloxacin and doxycycline-treated groups were 810, 910 for 14-day treatment and 1010, 710 for 21-day treatment. Delayed treatment with ciprofloxacin initiated 36- and 48-h postexposure resulted in 80 survival and was statistically no different than early postexposure 24 h treatment. This mouse model correlates closely with clinical observations of inhalational anthrax in humans and with earlier antibiotic studies in the non-human primate inhalational-anthrax model.

Subject Categories:

  • Medicine and Medical Research
  • Microbiology
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE